Highly sensitive fluorescence-based lateral flow platform for point-of-care detection of biomarkers in plasma

Meilin Zhu, Uwadiae Obahiagbon, Karen Anderson, Jennifer Blain Christen

Research output: Chapter in Book/Report/Conference proceedingConference contribution

4 Citations (Scopus)

Abstract

Point-of-Care (PoC) diagnostic devices, such as lateral flow tests, are often used in low and middle-income countries (LMIC) for low-cost disease detection. Most commercial lateral flow tests use colorimetric detection on a nitrocellulose substrate. In this paper, we present a multistep, fluorescence-based assay detection system, which can detect antibodies in plasma to recombinant protein. Fluorescence-based detection allows us to achieve higher sensitivity, while a nitrocellulose substrate enables fluid handling, high protein immobilization, rapid detection time, and affordability. As a proof-of-concept for detection of disease-specific biomarkers in plasma, we demonstrate the detection of antibodies in plasma to Epstein-Barr nuclear antigen-1 (EBNA-1) recombinant protein and to human papillomavirus (HPV) 16 E7 recombinant protein. We show that our detection system is able to detect EBNA-1-specific antibodies at a 1:10,000 plasma dilution and HPV 16 E7-specific antibodies at a 1:5,000 plasma dilution, indicating high sensitivity. This platform is a low-cost device that can detect fluorescence from labeled biomarkers on a lateral flow assay. Ultimately, we aim to adapt this system to detect HPV 16 and 18 biomarkers for cervical cancer screening in LMICs.

Original languageEnglish (US)
Title of host publication2017 IEEE Healthcare Innovations and Point of Care Technologies, HI-POCT 2017
PublisherInstitute of Electrical and Electronics Engineers Inc.
Pages249-252
Number of pages4
Volume2017-December
ISBN (Electronic)9781538613924
DOIs
StatePublished - Dec 19 2017
Event2017 IEEE Healthcare Innovations and Point of Care Technologies, HI-POCT 2017 - Bethesda, United States
Duration: Nov 6 2017Nov 8 2017

Other

Other2017 IEEE Healthcare Innovations and Point of Care Technologies, HI-POCT 2017
CountryUnited States
CityBethesda
Period11/6/1711/8/17

Fingerprint

Point-of-Care Systems
biomarkers
Biomarkers
Antibodies
platforms
Recombinant proteins
Fluorescence
Human papillomavirus 16
Plasmas
fluorescence
Recombinant Proteins
Nitrocellulose
antibodies
Nuclear Antigens
Collodion
Disease
Antigens
Dilution
costs
Papillomavirus E7 Proteins

ASJC Scopus subject areas

  • Health Informatics
  • Instrumentation
  • Health(social science)
  • Biomedical Engineering

Cite this

Zhu, M., Obahiagbon, U., Anderson, K., & Blain Christen, J. (2017). Highly sensitive fluorescence-based lateral flow platform for point-of-care detection of biomarkers in plasma. In 2017 IEEE Healthcare Innovations and Point of Care Technologies, HI-POCT 2017 (Vol. 2017-December, pp. 249-252). Institute of Electrical and Electronics Engineers Inc.. https://doi.org/10.1109/HIC.2017.8227631

Highly sensitive fluorescence-based lateral flow platform for point-of-care detection of biomarkers in plasma. / Zhu, Meilin; Obahiagbon, Uwadiae; Anderson, Karen; Blain Christen, Jennifer.

2017 IEEE Healthcare Innovations and Point of Care Technologies, HI-POCT 2017. Vol. 2017-December Institute of Electrical and Electronics Engineers Inc., 2017. p. 249-252.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Zhu, M, Obahiagbon, U, Anderson, K & Blain Christen, J 2017, Highly sensitive fluorescence-based lateral flow platform for point-of-care detection of biomarkers in plasma. in 2017 IEEE Healthcare Innovations and Point of Care Technologies, HI-POCT 2017. vol. 2017-December, Institute of Electrical and Electronics Engineers Inc., pp. 249-252, 2017 IEEE Healthcare Innovations and Point of Care Technologies, HI-POCT 2017, Bethesda, United States, 11/6/17. https://doi.org/10.1109/HIC.2017.8227631
Zhu M, Obahiagbon U, Anderson K, Blain Christen J. Highly sensitive fluorescence-based lateral flow platform for point-of-care detection of biomarkers in plasma. In 2017 IEEE Healthcare Innovations and Point of Care Technologies, HI-POCT 2017. Vol. 2017-December. Institute of Electrical and Electronics Engineers Inc. 2017. p. 249-252 https://doi.org/10.1109/HIC.2017.8227631
Zhu, Meilin ; Obahiagbon, Uwadiae ; Anderson, Karen ; Blain Christen, Jennifer. / Highly sensitive fluorescence-based lateral flow platform for point-of-care detection of biomarkers in plasma. 2017 IEEE Healthcare Innovations and Point of Care Technologies, HI-POCT 2017. Vol. 2017-December Institute of Electrical and Electronics Engineers Inc., 2017. pp. 249-252
@inproceedings{2391874a106143a8b1dda6e2c2832568,
title = "Highly sensitive fluorescence-based lateral flow platform for point-of-care detection of biomarkers in plasma",
abstract = "Point-of-Care (PoC) diagnostic devices, such as lateral flow tests, are often used in low and middle-income countries (LMIC) for low-cost disease detection. Most commercial lateral flow tests use colorimetric detection on a nitrocellulose substrate. In this paper, we present a multistep, fluorescence-based assay detection system, which can detect antibodies in plasma to recombinant protein. Fluorescence-based detection allows us to achieve higher sensitivity, while a nitrocellulose substrate enables fluid handling, high protein immobilization, rapid detection time, and affordability. As a proof-of-concept for detection of disease-specific biomarkers in plasma, we demonstrate the detection of antibodies in plasma to Epstein-Barr nuclear antigen-1 (EBNA-1) recombinant protein and to human papillomavirus (HPV) 16 E7 recombinant protein. We show that our detection system is able to detect EBNA-1-specific antibodies at a 1:10,000 plasma dilution and HPV 16 E7-specific antibodies at a 1:5,000 plasma dilution, indicating high sensitivity. This platform is a low-cost device that can detect fluorescence from labeled biomarkers on a lateral flow assay. Ultimately, we aim to adapt this system to detect HPV 16 and 18 biomarkers for cervical cancer screening in LMICs.",
author = "Meilin Zhu and Uwadiae Obahiagbon and Karen Anderson and {Blain Christen}, Jennifer",
year = "2017",
month = "12",
day = "19",
doi = "10.1109/HIC.2017.8227631",
language = "English (US)",
volume = "2017-December",
pages = "249--252",
booktitle = "2017 IEEE Healthcare Innovations and Point of Care Technologies, HI-POCT 2017",
publisher = "Institute of Electrical and Electronics Engineers Inc.",

}

TY - GEN

T1 - Highly sensitive fluorescence-based lateral flow platform for point-of-care detection of biomarkers in plasma

AU - Zhu, Meilin

AU - Obahiagbon, Uwadiae

AU - Anderson, Karen

AU - Blain Christen, Jennifer

PY - 2017/12/19

Y1 - 2017/12/19

N2 - Point-of-Care (PoC) diagnostic devices, such as lateral flow tests, are often used in low and middle-income countries (LMIC) for low-cost disease detection. Most commercial lateral flow tests use colorimetric detection on a nitrocellulose substrate. In this paper, we present a multistep, fluorescence-based assay detection system, which can detect antibodies in plasma to recombinant protein. Fluorescence-based detection allows us to achieve higher sensitivity, while a nitrocellulose substrate enables fluid handling, high protein immobilization, rapid detection time, and affordability. As a proof-of-concept for detection of disease-specific biomarkers in plasma, we demonstrate the detection of antibodies in plasma to Epstein-Barr nuclear antigen-1 (EBNA-1) recombinant protein and to human papillomavirus (HPV) 16 E7 recombinant protein. We show that our detection system is able to detect EBNA-1-specific antibodies at a 1:10,000 plasma dilution and HPV 16 E7-specific antibodies at a 1:5,000 plasma dilution, indicating high sensitivity. This platform is a low-cost device that can detect fluorescence from labeled biomarkers on a lateral flow assay. Ultimately, we aim to adapt this system to detect HPV 16 and 18 biomarkers for cervical cancer screening in LMICs.

AB - Point-of-Care (PoC) diagnostic devices, such as lateral flow tests, are often used in low and middle-income countries (LMIC) for low-cost disease detection. Most commercial lateral flow tests use colorimetric detection on a nitrocellulose substrate. In this paper, we present a multistep, fluorescence-based assay detection system, which can detect antibodies in plasma to recombinant protein. Fluorescence-based detection allows us to achieve higher sensitivity, while a nitrocellulose substrate enables fluid handling, high protein immobilization, rapid detection time, and affordability. As a proof-of-concept for detection of disease-specific biomarkers in plasma, we demonstrate the detection of antibodies in plasma to Epstein-Barr nuclear antigen-1 (EBNA-1) recombinant protein and to human papillomavirus (HPV) 16 E7 recombinant protein. We show that our detection system is able to detect EBNA-1-specific antibodies at a 1:10,000 plasma dilution and HPV 16 E7-specific antibodies at a 1:5,000 plasma dilution, indicating high sensitivity. This platform is a low-cost device that can detect fluorescence from labeled biomarkers on a lateral flow assay. Ultimately, we aim to adapt this system to detect HPV 16 and 18 biomarkers for cervical cancer screening in LMICs.

UR - http://www.scopus.com/inward/record.url?scp=85048486049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048486049&partnerID=8YFLogxK

U2 - 10.1109/HIC.2017.8227631

DO - 10.1109/HIC.2017.8227631

M3 - Conference contribution

VL - 2017-December

SP - 249

EP - 252

BT - 2017 IEEE Healthcare Innovations and Point of Care Technologies, HI-POCT 2017

PB - Institute of Electrical and Electronics Engineers Inc.

ER -